X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Merck Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs MERCK LTD - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA MERCK LTD CIPLA/
MERCK LTD
 
P/E (TTM) x 43.6 26.8 162.5% View Chart
P/BV x 3.6 3.0 119.6% View Chart
Dividend Yield % 0.4 0.9 37.9%  

Financials

 CIPLA   MERCK LTD
EQUITY SHARE DATA
    CIPLA
Mar-17
MERCK LTD
Dec-16
CIPLA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs6221,060 58.7%   
Low Rs458623 73.6%   
Sales per share (Unadj.) Rs181.9632.4 28.8%  
Earnings per share (Unadj.) Rs12.945.7 28.2%  
Cash flow per share (Unadj.) Rs29.362.3 47.0%  
Dividends per share (Unadj.) Rs2.0011.00 18.2%  
Dividend yield (eoy) %0.41.3 28.3%  
Book value per share (Unadj.) Rs155.7388.8 40.0%  
Shares outstanding (eoy) m804.5116.60 4,846.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.01.3 223.2%   
Avg P/E ratio x42.018.4 228.0%  
P/CF ratio (eoy) x18.413.5 136.4%  
Price / Book Value ratio x3.52.2 160.3%  
Dividend payout %15.524.1 64.6%   
Avg Mkt Cap Rs m434,51613,969 3,110.6%   
No. of employees `00023.01.6 1,455.7%   
Total wages/salary Rs m26,3381,487 1,771.6%   
Avg. sales/employee Rs Th6,349.16,631.9 95.7%   
Avg. wages/employee Rs Th1,143.0939.2 121.7%   
Avg. net profit/employee Rs Th449.3479.4 93.7%   
INCOME DATA
Net Sales Rs m146,30210,498 1,393.6%  
Other income Rs m2,287242 943.4%   
Total revenues Rs m148,58910,741 1,383.4%   
Gross profit Rs m24,7581,135 2,180.7%  
Depreciation Rs m13,229276 4,801.9%   
Interest Rs m1,5940-   
Profit before tax Rs m12,2221,102 1,108.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,798343 523.6%   
Profit after tax Rs m10,354759 1,364.4%  
Gross profit margin %16.910.8 156.5%  
Effective tax rate %14.731.1 47.2%   
Net profit margin %7.17.2 97.9%  
BALANCE SHEET DATA
Current assets Rs m87,3706,410 1,363.1%   
Current liabilities Rs m33,0818,828 374.7%   
Net working cap to sales %37.1-23.0 -161.1%  
Current ratio x2.60.7 363.8%  
Inventory Days Days8758 150.8%  
Debtors Days Days6238 162.3%  
Net fixed assets Rs m111,5671,406 7,932.8%   
Share capital Rs m1,609166 969.3%   
"Free" reserves Rs m123,6456,286 1,967.0%   
Net worth Rs m125,2546,455 1,940.5%   
Long term debt Rs m36,4540-   
Total assets Rs m209,5328,828 2,373.4%  
Interest coverage x8.7NM-  
Debt to equity ratio x0.30-  
Sales to assets ratio x0.71.2 58.7%   
Return on assets %5.78.6 66.3%  
Return on equity %8.311.8 70.3%  
Return on capital %8.517.1 49.8%  
Exports to sales %34.28.3 413.1%   
Imports to sales %8.321.0 39.6%   
Exports (fob) Rs m50,050869 5,756.8%   
Imports (cif) Rs m12,2032,209 552.4%   
Fx inflow Rs m51,066959 5,326.1%   
Fx outflow Rs m17,6782,612 676.8%   
Net fx Rs m33,388-1,653 -2,019.6%   
CASH FLOW
From Operations Rs m23,8241,070 2,225.7%  
From Investments Rs m-13,127-750 1,750.9%  
From Financial Activity Rs m-13,239-150 8,837.4%  
Net Cashflow Rs m-2,478171 -1,450.0%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 51.8 40.2%  
Indian inst/Mut Fund % 12.2 18.2 67.0%  
FIIs % 23.7 1.0 2,370.0%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 29.1 90.0%  
Shareholders   161,166 28,591 563.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   DR. DATSONS LABS  STRIDES SHASUN LTD  TTK HEALTHCARE  JUBILANT LIFE SCIENCES  BIOCON LTD  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Aug 23, 2017 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS